Physician profile
Mark A Burns
NPI 1811924483
$82,567.45
in general payments reported to CMS, 2019-2025
31 companies · $4,690 in 2025
The $4,690 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $7,634 · 2021: $8,956 · 2022: $12K · 2023: $4,448 · 2024: $7,010 · 2025: $4,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,660 · Travel and Lodging: $4,793 · Consulting Fee: $2,625 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,660.34 |
| Travel and Lodging | $4,793.39 |
| Consulting Fee | $2,625.00 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $36,057.03 | 2019-2025 | Carto 3, Na, Qdot Micro Catheter |
| Pfizer INC. | $11,667.55 | 2019-2025 | |
| Medtronic, INC. | $8,170.22 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Affera Mapping System |
| Abbott Laboratories | $6,763.63 | 2019-2025 | Aveir, Ensite Precision, Ensite |
| Medtronic Vascular, INC. | $5,661.40 | 2019-2020 | |
| Boston Scientific Corporation | $5,296.40 | 2019-2025 | Farapulse, General - Therapies, Rhythmia Mapping System |
| Acutus Medical, INC. | $3,218.75 | 2019-2021 | |
| Medical Device Business Services, INC. | $2,145.90 | 2019 | |
| Biotronik INC. | $463.90 | 2019-2020 | |
| Cardiofocus, INC. | $415.69 | 2020-2023 | Heartlight System |
| Cardiva Medical, INC. | $393.77 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Optowire |
| Impulse Dynamics (USA) INC. | $316.49 | 2022-2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $267.85 | 2019-2023 | |
| Abiomed | $267.14 | 2019-2022 | |
| Atricure, INC. | $258.49 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.69 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.58 | 2019-2025 | Lifevest |
| Bardy Diagnostics, INC. | $170.00 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $157.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.87 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.00 | 2021-2023 | Eliquis |
| Baylis Medical Company INC | $54.85 | 2021 | |
| Stryker Corporation | $49.11 | 2019 | |
| Amgen INC. | $32.19 | 2019-2020 | |
| Inspire Medical Systems, INC. | $30.68 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $29.94 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $27.18 | 2021 | |
| Penumbra, INC. | $21.00 | 2021 | |
| Cvrx, INC. | $18.93 | 2020 | |
| Elutia, INC. | $15.89 | 2020 | |
| Amarin Pharma, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.